Axplora, a global API and ADC manufacturing specialist, has announced a €50 million investment in its Mourenx facility in Southwest France. The expansion aims to strengthen its position in contract manufacturing for APIs and biologic drug substances, particularly in the
Antibody-Drug Conjugates (ADCs) – known as ‘the guided missiles of cancer therapy’ – are forecast to drive robust double-digit growth in contract development and manufacturing over the coming years, positioning them as a pivotal force in the biopharmaceutical landscape. ADCs
Axplora, a partner to Pharma companies and Biotechs for complex APIs, has appointed Martin Meeson as its new Chief Executive Officer (CEO). Meeson succeeds Sylke Hassel and brings with him over two decades of experience in managing and growing businesses
Axplora Contract Manufacturing & Development (CDMO) Profile Specialised in hazardous/explosive/highly energetic chemistry, cryogenic reactions for Fine Chemicals and Small molecule APIs 2 dedicated plants for HPAPIs. Market leader in chromatographic purification & ADC-Drug Substance CDMO Services: Small Molecule; Biologics Drug
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
